{"organizations": [], "uuid": "dbf56165aab811d4066e99af8005db6a4474c560", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-bristol-myers-squibb-and-illumina/brief-bristol-myers-squibb-and-illumina-announce-collaboration-to-develop-companion-diagnostics-for-bristol-myers-squibbs-oncology-immunotherapies-idUSFWN1RQ0M2", "country": "US", "domain_rank": 408, "title": "BRIEF-Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-13T23:28:00.000+03:00", "replies_count": 0, "uuid": "dbf56165aab811d4066e99af8005db6a4474c560"}, "author": "", "url": "https://www.reuters.com/article/brief-bristol-myers-squibb-and-illumina/brief-bristol-myers-squibb-and-illumina-announce-collaboration-to-develop-companion-diagnostics-for-bristol-myers-squibbs-oncology-immunotherapies-idUSFWN1RQ0M2", "ord_in_thread": 0, "title": "BRIEF-Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "illumina announce collaboration to develop companion diagnostics for bristol-myers squibb", "sentiment": "neutral"}, {"name": "brief-bristol-myers squibb and illumina announce co", "sentiment": "neutral"}, {"name": "min read    bristol-myers squibb co", "sentiment": "none"}, {"name": "develop companion diagnostics for bristol-myers squibb's oncology immunotherapies reuters staff", "sentiment": "none"}, {"name": "illumina", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 13, 2018 / 8:31 PM / Updated 8 minutes ago BRIEF-Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies Reuters Staff 1 Min Read \n  Bristol-Myers Squibb Co: \n* BRISTOL-MYERS SQUIBB AND ILLUMINA ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE COMPANION DIAGNOSTICS FOR BRISTOL-MYERS SQUIBB’S ONCOLOGY IMMUNOTHERAPIES \n* EXPANDS ILLUMINA’S ONCOLOGY OFFERINGS FOR NEXTSEQ 550DX \n* COS PLAN TO DEVELOP A DIAGNOSTIC VERSION OF ILLUMINA TRUSIGHT ONCOLOGY 500 ASSAY TO MEASURE POTENTIALLY PREDICTIVE GENOMIC BIOMARKERS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-13T23:28:00.000+03:00", "crawled": "2018-04-13T23:46:36.137+03:00", "highlightTitle": ""}